Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens
European Journal of Haematology · 2026-08 · 117 (2) · 409-421
DOI: 10.1111/ejh.70198 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 19.04.2026. Verfasst von Emiliano Barbieri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Chromosomes, Human, Pair 1, Antineoplastic Combined Chemotherapy Protocols, Gene Amplification. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes. However, the prognostic impact of +1q under daratumumab‐based treatments (DBTs) remains uncertain, since pivotal trials rarely reported +1q‐specific outcomes, and available real‐world data are limited and inconsistent. We conducted a single‐center retrospective study of 174 MM patients treated with DBTs between 2018 and 2023 to evaluate the prognostic effect of +1q. By FISH cytogenetic assessment we identified standard‐risk (SR), isolated +1q, +1q plus additional high‐risk CAs (+1q + HiRCAs), and non‐1q HiRCAs groups. The primary endpoint was progression‐free survival (PFS); secondary endpoints were time to next treatment (TTNT) and overall survival (OS). Median age was 72.0 years, median line of DBT administration was 2, and 125 patients (71.8%) received daratumumab‐lenalidomide‐dexamethasone (DaraRd). Cytogenetic data were available for 92 patients (52.9%): 43 SR, 11 non‐1q HiRCAs, 18 isolated +1q and 20 +1q + HiRCAs. After a median follow‐up of 30.7 months, isolated +1q was associated with significantly shorter PFS (HR 4.77, 95% CI: 1.68–13.53) and TTNT (HR 3.83, 95% CI: 1.33–11.09) versus SR, while +1q + HiRCAs had the worst outcomes across all endpoints (PFS HR 7.67; TTNT HR 5.81; OS HR 6.03). Multivariate analysis confirmed isolated +1q as an independent predictor of inferior PFS (HR 4.56, 95% CI: 1.61–12.95) and TTNT (HR 3.64, 95% CI: 1.26–10.55), with +1q + HiRCAs conferring the highest risks on all outcomes (PFS HR 8.36; TTNT HR 6.37; OS HR 6.18). Findings were consistent in the DaraRd subgroup. These findings demonstrate that +1q retains prognostic significance in the era of DBTs. Isolated +1q remains an independent factor of adverse prognosis, further worsened by co‐existing HiRCAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
- Clinical Trials Center, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
- Medical Genetics Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
ORCID-Profile: Emiliano Barbieri
Zitieren
APA
Barbieri, E., Arletti, L., Quaresima, M., Rivolti, E., Braglia, L., Fabiano, C., Alfano, A. M. R., Rinaldini, M., Bizzarri, V., Cattani, C., Marinelli, M., & Gamberi, B. (2026). Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens. European Journal of Haematology, 117(2), 409-421. https://doi.org/10.1111/ejh.70198
Vancouver
Barbieri E, Arletti L, Quaresima M, Rivolti E, Braglia L, Fabiano C, et al. Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens. European Journal of Haematology. 2026;117(2):409-421. doi:10.1111/ejh.70198
BibTeX
@article{Barbieri2026,
author = {Barbieri, Emiliano and Arletti, Laura and Quaresima, Micol and Rivolti, Elena and Braglia, Luca and Fabiano, Cecilia and Alfano, Adriana Maria Rita and Rinaldini, Monia and Bizzarri, Veronica and Cattani, Chiara and Marinelli, Maria and Gamberi, Barbara},
title = {Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {2},
pages = {409--421},
doi = {10.1111/ejh.70198}
}
EUVIMED